pre-IPO PHARMA

COMPANY OVERVIEW

Aphios (www.aphios.com) is a clinical stage biotechnology company developing green enabling technology platforms to improve drug discovery, manufacturing, nanotechnology drug delivery and pathogenic safety. Based on these platforms, enhanced therapeutics to improve quality-of-life and treat chronic diseases such as prostate and pancreatic cancers, infectious diseases such as HIV/AIDS, and Central Nervous System disorders such as Alzheimer’s disease and Multiple Sclerosis in an environmentally sustainable manner.


LOCATION

  • Woburn, MA, USA

  • THERAPEUTIC AREAS

  • Metabolic Disorders
  • Neurological DIsorders
  • Oncology

  • WEBSITE

    https://www.aphios.com/


    CAREER WEBSITE

    https://www.aphios.com/about-us/careers.html


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Jul 7, 2022

    Aphios Pharma LLC to Host Webinar on the Business of Cannabis as a Pharmaceutical Medicine on Thursday, July 14, 2022 at 12:00 pm EST


    Jun 21, 2022

    Aphios Pharma LLC to Host Webinar on the Science and Technology of Cannabis as a Medicine on Thursday, June 23rd, 2022 at 1pm EST


    Feb 8, 2022

    Aphios Granted US Patent For Combination HIV Latency Nanoparticles Towards an HIV Cure


    Nov 10, 2021

    Aphios Granted Chinese Patent for Novel Bryoid to Treat Alzheimer’s Disease


    Mar 30, 2021

    Aphios Granted US Patent for Novel, More Potent Bryoid to Treat Alzheimer’s diseases, HIV-1 Latency, Prostate Cancer, Glaucoma and Multiple Sclerosis


    For More Press Releases


    Google Analytics Alternative